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Key points 7 
- Exposure to remifentanil contributes to an increased risk of pulmonary aspiration 8 
- We employed a novel high resolution pressure-flow analysis to quantify the 9 
swallowing-related biomechanical changes across the upper esophageal sphincter 10 
(UES) during remifentanil exposure in healthy volunteers.  11 
- Remifentanil increased residual UES pressure, shortened the time period of UES 12 
opening and shortened the latencies between the different phases of the stereotypical 13 
UES relaxation sequence. 14 
- Reduced duration of bolus flow during shortened UES opening in concert with 15 
increased hypopharyngeal distension pressures are mechanically consistent with 16 
increased flow resistance due to a more rapid bolus flow rate.  17 
- These biomechanical changes are congruent with modification of the physiologic 18 
neuro-regulatory mechanism governing accommodation to bolus volume. 19 
  20 
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Abstract 1 
 2 
Exposure to remifentanil contributes to an increased risk of pulmonary aspiration, likely 3 
through reduced pharyngeal contractile vigour and diminished bolus propulsion during 4 
swallowing. Here, we employed a novel high resolution pressure-flow analysis to quantify 5 
the biomechanical changes across the upper esophageal sphincter (UES). Eleven healthy 6 
young participants (mean age 23.3±3.1 years, 7 male) received remifentanil via intravenous 7 
target controlled infusion with an effect-site concentration of 3 ng/ml. Before and 30 min 8 
following commencement of remifentanil administration, participants performed ten 10 ml 9 
saline swallows while pharyngo-esophageal manometry and electrical impedance data were 10 
recorded using a 4.2 mm diameter catheter housing 36 circumferential pressure sensors. 11 
Remifentanil significantly shortened the time period of UES opening (p<0.001) and increased 12 
residual UES pressure (p=0.003). At the level of the hypopharynx, remifentanil significantly 13 
shortened the time latency from maximum bolus distension to peak contraction (p=0.004) and 14 
significantly increased intrabolus distension pressure (p=0.024). Novel mechanical states 15 
analysis revealed that the latencies between the different phases of the stereotypical UES 16 
relaxation sequence were shortened by remifentanil. Reduced duration of bolus flow during 17 
shortened UES opening in concert with increased hypopharyngeal distension pressures are 18 
mechanically consistent with increased flow resistance due to a more rapid bolus flow rate. 19 
These biomechanical changes are congruent with modification of the physiologic neuro-20 
regulatory mechanism governing accommodation to bolus volume.  21 
 22 
 23 
Abbrevations. CNS, Central nervous system; CP, cricopharyngeus; CPG, central pattern 24 
generator; DSG, Dorsal swallowing group; NTS, Nucleus tractus solitarius; UCI, Upper 25 
esophageal sphincter contractile integral; UES, Upper esophageal sphincter. 26 
 27 
  28 
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Introduction 1 
Recent research into potential underlying causes of postoperative respiratory complications, 2 
such as pneumonia, suggests that exposure to remifentanil, a short-acting opioid analgesic 3 
drug, can induce swallowing difficulties (29) and an increased incidence of pulmonary 4 
aspiration (28). Remifentanil-induced swallowing difficulties are characterised by reduced 5 
pharyngeal contractile vigour and diminished bolus propulsion as reflected by an increase in 6 
the Swallowing Risk Index (27), a novel pressure- and electrical impedance-based composite 7 
score of swallowing function (20,21,22). At the level of the upper esophageal sphincter 8 
(UES), residual pressure and overall flow resistance also increase (27). 9 
These findings suggest that changes in the neuro-biomechanical mechanisms driving and 10 
coordinating pharyngeal bolus propulsion, as well as UES relaxation and opening, may 11 
contribute to the swallowing difficulties reported following exposure to remifentanil. 12 
Remifentanil is an opioid analgesic drug which primarily acts as a opioid receptor agonist. 13 
opioid receptors are abundant in peripheral vagal afferents (4) and are the predominant 14 
opioid receptor in the nucleus tractus solitarius (NTS) (8, 34). Both of these systems play a 15 
critical role in integrating peripheral afferent feedback into an effective and safe swallowing 16 
response. Therefore, it is possible that remifentanial affects swallowing function via 17 
modification of peripheral or central synaptic mechanisms, or both. 18 
Based on this premise and in the context of the biomechanical effects of remifentanil on 19 
pharyngo-esophageal swallowing that we described previously (27, 28, 29), we hypothesised 20 
that exposure to remifentanil results in quantifiable changes in pharyngeal bolus propulsion 21 
and UES relaxation and opening, producing knock-on effects such as increased flow 22 
resistance across the UES and overall aspiration risk. To test this hypothesis, we conducted 23 
an in-depth analysis of the effects of remifentanil on swallowing function using recently 24 
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nuanced analytical methods aimed specifically at quantifying critical event timing during the 1 
act of swallowing. Specifically, we evaluated the relationship between intraluminal pressure 2 
and luminal diameter, as assessed by concurrent pharyngo-esophageal high resolution 3 
intraluminal pressure and impedance recording, off and on remifentanil. 4 
 5 
Methods and Materials 6 
Subjects 7 
We report data from 11 healthy young participants (mean age 23.3±3.1, 7 male) who were 8 
previously enrolled in a double-blind, randomised, placebo-controlled, cross-over study of 9 
opioid drugs (27). In this previous publication, we reported pharmacodynamic effects at two 10 
time points, 15 min and 30 min, following commencement of remifentanil infusion. As the 11 
steady state plasm concentration is rapidly achieved by target controlled infusion systems, 12 
and there were no differences between the time points, in this follow up physiological 13 
analysis we report the effects at 30 min compared to baseline only. Data were collected at the 14 
Department of Anaesthesiology, University Hospital in Örebro, Sweden, following informed 15 
consent being provided by each participant. This study was approved by the Central Ethics 16 
Review Board in Uppsala, Sweden. None of the participants reported any current or past 17 
symptoms of dysphagia or upper gastrointestinal diseases, smoked or took any medications 18 
that could affect pharyngeal or esophageal function. Potential participants were excluded if 19 
they were pregnant, breastfeeding, or had previously participated in a medical study. 20 
 21 
Treatment 22 
Remifentanil was administered via intravenous infusion with an effect-site target 23 
concentration of 3 ng/ml using target controlled infusion (Minto Model, Alaris PK syringe 24 
pump, Alaris Medical Nordic AB, Sollentuna, Sweden). 25 
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 1 
High resolution impedance manometry 2 
Manometry and impedance data were recorded using a 4.2 mm diameter catheter housing 36 3 
circumferential pressure sensors that were spaced 1 cm apart and 18 2-cm long impedance 4 
segments (Sierra Scientific Instruments, Inc., Los Angeles, CA). Following standard 5 
calibration in accordance with the manufacturer’s specifications, catheter placement was 6 
performed transnasally with sensors straddling the entire pharyngo-esophageal segment. 7 
Following a 5 minute accommodation period, participants ingested 10 ml saline boluses on 8 
command that were administered orally via a syringe at > 20 s intervals. We analysed 10 9 
swallows that were recorded at baseline and a further 10 swallows recorded 30 min following 10 
drug infusion for each participant.   11 
 12 
Analysis of pressure and impedance recordings 13 
Swallows were analysed consecutively using a purpose-designed software (based in 14 
MATLAB version 8.5.0.197613–R2015a; MathWorks Inc). Colour pressure isocontour plots 15 
of each swallow file were opened, the pressure and impedance data were automatically 16 
interpolated (Piecewise Cubic Hermite Interpolating Polynomial) to increase the dataset to a 17 
1 mm spatial resolution. 18 
Four space-time landmarks were determined on the plot. These are described below (see also 19 
Figure 1): 20 
1. The time of onset of complete UES relaxation, indicating UES opening. 21 
2. The time of offset of complete UES relaxation, indicating UES closure. 22 
3. The apogee position of the UES high pressure zone, defined by visualisation of 23 
the upward movement of the UES high pressure zone to determine the highest 24 
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position of the proximal edge of the high pressure zone during the swallowing 1 
event. 2 
4. The distal margin position of the UES high pressure zone, defined by the lowest 3 
position of the distal edge of the high pressure zone pre- and/or post-swallow. 4 
Guided by definition of these landmarks, values for a range of swallow function variables 5 
were derived. 6 
Swallow function variables 7 
Swallow variables were separated into four sub-classes: 1) measures of flow/event timing, 2) 8 
measures distension pressure, 3) measures of luminal cross-sectional area and 4) measures of 9 
contractility. We provide specific details of all variables below (see also Figure 1). 10 
During passage of a highly conductive bolus, the inverse of impedance or admittance 11 
(expressed in millisiemens, mS, the unit of electric conductance) increases when the lumen is 12 
increasing in diameter and decreases when the lumen is decreasing in diameter. The 13 
maximum admittance corresponds to the time and position where the lumen is most 14 
conductive. In normal circumstances this identifies the axial centre, or most distended part, of 15 
the intra-bolus bolus domain during transport (9, 16, 23). Hence, pressure measured at, or 16 
timing of, maximum admittance is an accurate measure of intrabolus distension pressure and 17 
timing of maximum distension respectively.  18 
The UES can undergo up to 2cm or more elevation before complete UES relaxation. The 19 
manometry catheter itself may also elevate during swallowing, asynchronous to UES 20 
elevation. UES pressure and impedance data were therefore analysed within an area of 21 
interest corresponding to the region from the distal margin of the UES high pressure zone to 22 
the estimated apogee position of the UES during swallow. The maximum axial UES pressure 23 
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during the swallow was measured within the limits of UES area of interest over time. The 1 
location of maximum axial pressure was used to track the superior and inferior movement of 2 
the UES based on the method of Ghosh and colleagues (7), now routinely referred to at the 3 
‘e-sleeve’ method (Figure 1). Consecutive pressure and admittance values mapped to the 4 
corresponding position of the UES over time can be used to derive an optimal profile of 5 
pressure and admittance during the swallow. 6 
The following flow timing measures were determined: 1) the UES opening period, based on 7 
the UES admittance curve (UES rapid admittance upstroke to the inflexion of the admittance 8 
downstroke); 2) time from opening to maximum hypopharyngeal distension (UES admittance 9 
upstroke to hypopharyngeal admittance peak); 3) time from maximum hypopharyngeal bolus 10 
distension to maximal contraction (admittance peak to contraction peak) and 4) 11 
hypopharyngeal bolus presence (hypopharyngeal admittance upstroke to inflexion on 12 
downstroke). 13 
The following pharyngeal and UES distension pressures were determined: 1) three discrete 14 
hypopharyngeal intrabolus pressures (IBP1, 2 and 3), measured 1 cm proximal to the UES 15 
apogee position and temporally aligned to maximum admittance (maximum distension) at the 16 
hypopharynx (IBP1), maximum admittance at the UES apogee (IBP2) and maximum 17 
admittance 1 cm below the UES apogee (IBP3). Using the ‘e-sleeve’ method based on 18 
maximum axial UES pressures (as described above): 2) the UES residual pressure and 3) the 19 
UES 0.25 sec integrated relaxation pressure. This is the median of all lowest UES pressures 20 
(contiguous or non-contiguous) recorded measured over a 0.25 sec period (32). 21 
The maximum luminal cross-sectional area during bolus flow was inferred based on 22 
maximum admittance at the hypopharynx, UES apogee and 1 cm below the UES apogee (23). 23 
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The following pharyngeal and UES contractility measures were determined: 1) 1 
hypopharyngeal peak pressure at 1 cm proximal to the UES apogee position; 2) the 2 
pharyngeal contractile integral based on pressures for the whole pharynx greater than 20 mm 3 
Hg from onset of complete UES relaxation to 0.5 sec after offset of relaxation. 3) Using the 4 
e-sleeve method based on maximum axial UES pressures, basal UES pressure was 5 
determined using the average pressure up to 0.25 sec prior to complete UES relaxation. 4) 6 
Post-relaxation peak pressure was determined by the maximum post-relaxation pressure up to 7 
1 sec after relaxation offset. 5) The UES contractile integral (UCI) was determined based on 8 
post-relaxation pressures greater than 20 mmHg up to 1 sec after relaxation offset. 9 
Mechanical states analysis 10 
In the cricopharyngeus (CP) muscle segment, activation of inhibitory or excitatory neural 11 
inputs during swallowing changes the diameter of the CP lumen, consequently modifying 12 
intraluminal pressure and bolus flow across the sphincter. This real-time relationship between 13 
UES luminal opening and corresponding changes in intraluminal pressure recorded at the 14 
same location was recently used to describe a novel method of inferentially evaluating the 15 
mechanical states of the contributing musculature, in particular the CP fibres (23). Omari and 16 
colleagues (23, 24) demonstrated the feasibility and validity of this technique, identifying 17 
eight UES mechanical states ubiquitously present in unimpaired swallowing. For example, 18 
UES mechanical states analysis was able to detect differences in UES biomechanics between 19 
age-matched non-dysphagic volunteers and individuals with swallowing impairment 20 
secondary to motor neuron disease, and these corresponded to the known neural innervation 21 
patterns of the UES (23). Furthermore, in healthy volunteers mechanical states analysis has 22 
been shown to successfully predict the activity of the CP-muscle as measured by CP-23 
electromyography. Mechanical states analysis was used in the present study to inferentially 24 
characterise the neurological modulations in UES innervation that may contribute to the 25 
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changes in swallowing function recently reported during exposure to remifentanil (27). 1 
Specifically, we used mechanical states analysis to deduce the duration of ‘pause’ of neural 2 
activation of the CP muscle (23, 24). As illustrated in Figure 2, the pause was defined by the 3 
period from auxotonic (lumen opening) relaxation (marking deactivation of CP neural inputs) 4 
to auxotonic (lumen closing) contraction (marking CP re-activation). 5 
 6 
Statistical analysis 7 
Variables measured before and after exposure to remifentanil were compared by paired t-test 8 
and presented as mean ± standard error (t statistic). A p-value <0.05 was considered 9 
statistically significant. 10 
 11 
 12 
Figure 1. Analysis was performed using a semi-automated software routine. The first step in 13 
the analysis was to manually input the positions of the UES distal margin and UES apogee 14 
and the approximate time of UES opening and closure based on the relaxation onset and 15 
offset. The software then created a magnified pressure topography plot of the UES region that 16 
was automatically populated with relevant analysis landmarks defining where pressure, 17 
admittance and timing variables are measured (top panel). Axial movement of the UES high 18 
12 
 
pressure zone was determined by the position of maximum ‘e-sleeve’ pressure. Consecutive 1 
pressure and admittance values mapped to the corresponding position of the UES over time 2 
was used to derive an optimal profile of pressure and admittance during the swallow. The 3 
UES pressure-admittance curve (bottom panel) was used to adjust the onset of UES opening, 4 
based on the rapid admittance upstroke, and UES closure based on the inflexion of the 5 
admittance downstroke. 6 
 7 
Results 8 
Remifentanil exposure significantly altered the timing of several, but not all, sub-components 9 
of the swallowing mechanism. The main effects are demonstrated in Figure 2 with mean 10 
values shown in Table 1. At the level of the UES, remifentanil exposure for 30 min 11 
significantly shortened the time period of UES opening (Figure 2 A vs. E and C vs. G) and 12 
increased residual UES pressures (Table 1). At the level of the hypopharynx, remifentanil 13 
significantly shortened the time latency from maximum bolus distension (time of maximum 14 
admittance) to peak contraction (time of maximum pressure) (Figure 2 B vs. F) and 15 
significantly increased intrabolus distension pressures (Table 1). UES and pharyngeal 16 
maximum admittance (bolus distension area) was not significantly different overall (Table 1). 17 
In contrast to the timing and distension variables, the contractility of the pharynx and UES 18 
was unaffected by remifentanil in this group of participants. 19 
Using mechanical states analysis, we could demonstrate changes in the mechanical state of 20 
the muscle consistent with activation and deactivation of the CP muscle by corticobulbar 21 
motor neurones. The CP muscle is tonically active at rest and undergoes neurally mediated 22 
deactivation immediately prior to UES opening (Lang, 2006). Following UES opening, 23 
inferred neural activity follows a pattern of re-activation, tonic activation and then 24 
deactivation, returning to a steady tonic activation state; i.e., basal conditions (Figure 2D). 25 
This stereotypical sequence of events was also observed after exposure to remifentanil 26 
13 
 
(Figure 2E). However, as with other temporal variables, the latencies between the different 1 
phases of the sequence were shortened, as indicated by the reduced period of predicted CP 2 
pause (Table 1). 3 
 4 
 5 
Figure 2. Effects of remifentanil on swallowing biomechanics based on example 10 ml 6 
swallows recorded in a subject before (A–D) and after (E–H) remifentanil exposure.  7 
A, E: Pressure isocontour plots of the pharynx and UES region as per Figure 1. The black 8 
dotted line shows location of maximum axial UES pressure during the swallow and tracks the 9 
superior movement of the UES high pressure zone from its resting position to its apogee 10 
position and back to resting over the time-base. 11 
Note that the maximum admittance line (purple) and peak pressure  line (black) are closer 12 
together in E, indicating  shorter distention-contraction latency; 13 
B, F: Hypopharyngeal pressure (black line) and admittance (purple line) profiles recorded at 14 
1cm proximal of the apogee position. Note that the hypopharyngeal admittance and pressure 15 
peaks are closer in time in F indicating a shorter distention-contraction latency. 16 
14 
 
C, G: UES pressure (black line) and admittance (purple line) profiles defined at maximum 1 
axial UES pressure (shown A and B). Note that the UES opening period defined by the 2 
admittance inflexion points is shorter in G;  3 
D, H: UES mechanical states analysis defining when the muscle state is tonically active, 4 
activating (contracting) or de-activating (relaxing) due to neural inputs. Note that the CP 5 
pause, defined by the period from de-act (marking onset of inferred neural deactivation) to 6 
act (marking offset of inferred deactivation), is shorter in H. However, the sequence order of 7 
CP muscle activation (i.e., tonic activation–deactivation–re-activation–tonic activation–8 
deactivation–tonic activation) remains unchanged by remifentanil. 9 
  10 
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 1 
Table 1. Effects of 30 min exposure of remifentanil on measures of swallowing function. 2 
Mean ± standard error (SEM) of all swallows from all participants are presented at each time 3 
point. The t statistic and p-value of the pairwise comparison are also shown.  4 
 5 
6 
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Discussion 1 
In young healthy subjects, exposure to remifentanil caused a delay in the timing of the onset 2 
of UES relaxation and opening during the swallow sequence that reduced the duration of flow 3 
during UES relaxation and opening. Pharyngeal contractile forces driving propulsion of the 4 
bolus through the open UES, as well as extrinsic contractile forces responsible for UES 5 
distraction and the extent of UES opening, appeared to be least affected by remifentanil 6 
exposure. Finally, hypopharyngeal distension pressures increased in circumstances where 7 
propulsive forces and UES aperture were unaffected, an observation mechanically consistent 8 
with increased flow resistance due to more rapid bolus flow rate in conjunction with a shorter 9 
flow permissive time. These biomechanical changes are analogous to differences previously 10 
observed between larger and smaller bolus volumes (5, 13) We propose that together, these 11 
findings suggest that remifentanil exposure experimentally induces a specific sensory deficit 12 
and that the resulting biomechanical changes are congruent with modification of the 13 
neuroregulatory mechanisms governing the accommodation to bolus volume; specifically, 14 
during exposure to remifentanil, a motor response appropriate for a smaller bolus is generated 15 
even in the presence of a much larger bolus. 16 
There is biomechanical as well as neurophysiological evidence to support this hypothesis. 17 
Biomechanically, it is likely that the shortened UES opening duration was the main driver 18 
underlying the increased UES residual pressures, shortened time latency from maximum 19 
bolus distension to peak contraction and increased maximum bolus distension pressures. 20 
These knock-on effects are in line with biomechanical patterns that could be expected to 21 
occur when a larger bolus is swallowed using a swallowing pattern designed for a smaller 22 
bolus volume. Specifically, in the unimpaired system, swallowing larger bolus volumes leads 23 
to earlier and larger increases in UES diameter compared to when smaller bolus volumes are 24 
swallowed (5, 13). This accommodation of UES compliance is physiologically driven by 25 
17 
 
vagal afferent feedback regarding bolus volume, which enables pharyngo-esophageal 1 
segment compliance to be modified so that it accommodates a faster rate of bolus flow while 2 
maintaining low flow resistance. In line with this, using mechanical states analysis, we 3 
recently demonstrated that larger bolus volumes were accompanied by greater UES 4 
admittance (i.e., greater bolus distension area), and longer and faster UES opening, while 5 
pharyngeal and UES contractile patterns were less affected by bolus volume (23). In contrast, 6 
remifentanil exposure in the present study significantly shortened UES opening duration 7 
compared to control swallows, a finding consistent with shorter neural inhibition of the CP 8 
segment. This was evidenced in particular by the shortened CP pause duration, indicating a 9 
shorter period of neural CP deactivation on remifentanil. This resulted in impaired bolus flow 10 
across the sphincter region, consequently increasing UES residual pressures, shortening the 11 
latency between maximum bolus distension to peak contraction and increasing 12 
hypopharyngeal intrabolus distension pressures. Reduced sensory feedback during 13 
remifentanil exposure, misinterpreted as the presence of a smaller bolus, would likely induce 14 
this effect. The exact neurophysiological mechanisms underlying remifentanil-induced 15 
modulation of sensory feedback during swallowing are not yet known; however, as a 16 
opioid receptor agonist, remifentanil would likely have modified swallowing-related 17 
activity in vagal afferent pathways as well as neural circuits in the NTS as opioid receptors 18 
are abundant in both of these circuits (4, 8, 34). The scope of the current study did not allow 19 
to determine whether remifentanil exerts its effects on swallowing function via modification 20 
of opioid receptors peripherally, centrally, or both. However, previous literature supports 21 
the notion that either site of modification may have contributed to the biomechanical effects 22 
reported here. 23 
Action on peripheral vagal afferents 24 
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The region of the UES is primarily composed of the inferior pharyngeal constrictor and the 1 
CP muscle and is innervated by vagal afferents, in particular via the pharyngeal plexus 2 
proximally and the recurrent laryngeal nerve distally (18) and both vagal afferent pathways 3 
contain a significant number of opioid receptors (4). In the context of cough it has been 4 
demonstrated that exposure to the opioid receptor agonist H-Tyr-D-Arg-Gly-Phe-(4-NO2)-5 
Pro-NH2 (BW443C) results in effective inhibition of an experimentally induced cough reflex 6 
in guinea pigs (3) and anaesthetised cats (1). Likewise, BW443C reduced capsaicin-evoked 7 
discharges in pulmonary and bronchial vagal C-fibre receptors in anaesthetised cats (2). The 8 
antitussive effects of morphine and codeine, themselves opioid receptor agonists, can be 9 
countered by the peripherally-acting opioid antagonist N-methyl nalorphine (3) and 10 
levallorphan, which, like BW443C, have limited ability to cross into the central nervous 11 
system (CNS) (14). Taken together, these animal studies provide some evidence that 12 
opioid receptor agonists have the ability to interfere with sensory vagal afferents at a 13 
peripheral level. Given the importance of peripheral vagal feedback during swallowing, it is 14 
possible that, through activation of opioid receptors, remifentanil reduced the peripheral 15 
afferent input conveying information about bolus properties directly to the NTS. The NTS is 16 
the main sensory hub related to swallowing in the brainstem and a critical part of the 17 
swallowing central pattern generator (CPG) (11). Interestingly, the NTS also houses a 18 
significant number of opioid receptors (8, 34). It is therefore also possible that the effects 19 
of remifentanil on swallowing originate, at least in part, at a central level. 20 
  21 
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Action at a central level 1 
The NTS is located in the dorsomedial medulla and forms an integral part of the dorsal 2 
swallowing group (DSG), a network of premotor neurons thought to generate the sequential 3 
firing pattern required for the rhythmic oropharyngeal and esophageal muscle contractions 4 
required during swallowing (12). The NTS is the main sensory hub for vagal afferent input 5 
from the oropharynx, and almost all oropharyngeal NTS neurons receive input from vagal 6 
afferents (12). Animal experiments have shown that stimulation of SLN afferents evokes a 7 
short latency response in both oropharyngeal and proximal esophageal DSG neurons, 8 
providing evidence that vagal sensory afferents monosynaptically innervate this part of the 9 
swallowing CPG (15, 25). Importantly in the context of the present findings, several previous 10 
studies have reported that sensory feedback is a powerful modulator of neuronal activation in 11 
the swallowing CPG (10, 6) that can adjust motor outputs depending on the bolus swallowed 12 
(6). Given the high level of opioid receptors in the NTS, it is therefore likely that any 13 
centrally acting opioid receptor agonist can modulate the activity of the swallowing CPG, 14 
in particular of the DSG located in the NTS. In vitro studies of the rat NTS support this 15 
notion. For example, the opioid receptor agonist D-Ala2, N-MePhe4, Gly-ol5-enkephalin 16 
(DAMGO) is able to block excitatory glutamate-mediated postsynaptic potentials and in a 17 
subgroup of cells also blocked cellular activity via presynaptic mechanisms (26). In addition, 18 
studies in rats demonstrated that opioid agonists reduce activity of Ca2+ channels in sensory 19 
neurons (30) including the nodose ganglia (19), which contribute significant vagal afferent 20 
input to the NTS. Inhibition of Ca2+ currents in the terminals of presynaptic neurons would 21 
result in decreased neurotransmitter release, a common strategy associated with opioid 22 
receptors throughout the CNS (19). In the present study, modification of the NTS-driven 23 
swallowing motor sequence by altered vagal afferent input on remifentanil was reflected in 24 
the shorter period of UES deactivation. It is worth noting that modulation of sensory afferent 25 
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feedback by remifentanil as outlined here is not specific to this drug, but may equally apply 1 
to other opioid agonists. 2 
Interestingly, remifentanil has previously been demonstrated to induce muscle rigidity, a 3 
common side effect of anilidopiperidine-opioids, in particular remifentanil (33, 31). 4 
Therefore, it may alternatively be possible that the biomechanical symptoms observed in this 5 
study, in particular the shortened UES opening duration, are due to remifentanil-induced 6 
rigidity of the UES musculature. Our mechanical states data argue against this possibility, as 7 
neither the rate nor the overall extent of UES opening were affected by remifentanil (Figure 8 
2C, 2G). If rigidity was a major contributor to the findings reported here, then either (or both) 9 
measures would be expected to be reduced due to decreased UES compliance. In addition, 10 
muscle rigidity may occur when remifentanil is delivered as a high dose bolus (33), but it is 11 
unlikely that this occurred over the 30 minute period of target controlled infusion of 12 
remifentanil in this study. We acknowledge the limitation of not having included a placebo 13 
control group in this study or not having tested different bolus volumes. The latter in 14 
particular may have provided further support for the hypothesis that modulation of sensory 15 
feedback occurred if there had been a shift to the right of the volume opening curve. 16 
However, we draw attention to the striking effects observed during exposure to remifentanil, 17 
which were not observed during baseline swallows in this study. Similarly, a previous study 18 
of the effects of remifentanil on swallowing did not demonstrate any changes in swallowing 19 
function in the placebo control condition (28).    20 
Taken together, there is compelling evidence to suggest that exposure to remifentanil reduced 21 
the sensory input of the swallowed 10 ml bolus, either via peripheral or central inhibitory 22 
mechanisms, or both, which was misinterpreted by the DSG as the presence of a much 23 
smaller bolus. Accordingly, the resulting swallowing motor plan, primarily characterised by a 24 
21 
 
shortened UES deactivation and opening period compared to the 10 ml control swallows, was 1 
unable to accommodate the larger swallowed bolus. The knock-on effects of increased UES 2 
residual pressure, increased intrabolus distension pressure and shortened latency between 3 
maximum bolus distension and the peak contraction support this notion as they are all 4 
indicative of a larger bolus travelling more rapidly through a UES lumen that is open for a 5 
shorter period. The effects reported here contribute to the previous literature in this field 6 
documenting increased occurrence of aspiration (28) and pharyngeal swallowing impairment 7 
(27) during exposure to remifentanil, highlighting the clinical relevance of this area of 8 
research.  9 
  10 
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